SCHEMBL3736173

SCHEMBL3736173

COc1ccc(Cn2cc(C=O)nn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
HSP90AA1 P07900 2/20 0.51
HSP90AB1 P08238 2/20 0.51
PTGS2 P35354 1/20 0.51
CYP19A1 P11511 2/20 0.50
HDAC1 Q13547 1/20 0.48
SNCA P37840 1/20 0.47
CMA1 P23946 1/20 0.46
CCNK O75909 1/20 0.44
CDK12 Q9NYV4 1/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4316416 0.85 MEN1 (0.55) MEN1KMT2ANPC1RAB9AHSP90AA1
SCHEMBL15803475 0.84 RAB9A (0.54) MEN1KMT2ANPC1RAB9APTGS2
SCHEMBL28032608 0.81 MEN1 (0.51) MEN1KMT2ANPC1RAB9AHSP90AA1
SCHEMBL4959659 0.81 CYP19A1 (0.56) MEN1KMT2ANPC1RAB9AHSP90AB1
SCHEMBL31666980 0.80 MEN1 (0.50) MEN1KMT2ANPC1RAB9AHSP90AA1
SCHEMBL28623300 0.80 HDAC1 (0.50) MEN1KMT2ANPC1RAB9AHSP90AA1
SCHEMBL28656682 0.80 HDAC1 (0.50) MEN1KMT2ANPC1RAB9AHSP90AA1
SCHEMBL1196122 0.79 CACNA1G (0.49) MEN1KMT2ANPC1RAB9APTGS2
SCHEMBL31667476 0.78 MEN1 (0.48) MEN1KMT2ANPC1RAB9AHSP90AA1
SCHEMBL24570444 0.78 HSD17B10 (0.51) MEN1KMT2ANPC1RAB9AHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 EP disclosed
WO-2025064829-A1 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-03-27 WO disclosed
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 US disclosed
EP-4448522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-10-23 EP disclosed
CN-118488953-A Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors 豪夫迈·罗氏有限公司 2024-08-13 CN disclosed
WO-2023110958-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-22 WO disclosed
EP-1713794-B1 HETEROCYCLE GRAFTED MONOMERS AND RELATED POLYMERS AND HYBRID INORGANIC-ORGANIC POLYMER MEMBRANES TOYOTA TECHNICAL CT U S A INC (US) 2014-05-07 EP disclosed
US-7829580-B2 Cyclic amine derivative having heteroaryl ring SANKYO COMPANY, LTD. (JP) 2010-11-09 US disclosed
US-7576165-B2 Having an acid group attached to the hybrid inorganic-organic matrix; and a nitrogen-containing heterocycle attached to the hybrid inorganic-organic matrix, wherein the nitrogen-containing heterocycle is selected from 1,2,4-triazole,1,2,3-triazole, 1H-benzotriazole, pyrimidine, for example; fuel cells GEORGIA INSTITUTE OF TECHNOLOGY (US) 2009-08-18 US disclosed
CN-1910151-A Cyclic amine derivative with heteroaryl ring SANKYO CO (JP) 2007-02-07 CN disclosed
US-20060270706-A1 Cyclic amine derivative having heteroaryl ring SANKYO COMPANY, LTD. (JP) 2006-11-30 US disclosed
EP-1713794-A2 HETEROCYCLE GRAFTED MONOMERS AND RELATED POLYMERS AND HYBRID INORGANIC-ORGANIC POLYMER MEMBRANES Toyota Technical Center, U.S.A., Inc. (US) 2006-10-25 EP disclosed
EP-1695962-A1 CYCLIC AMINE DERIVATIVE HAVING HETEROARYL RING Sankyo Company, Limited (JP) 2006-08-30 EP disclosed
US-20060111530-A1 Heterocycle grafted monomers and related polymers and hybrid inorganic-organic polymer membranes TOYOTA MOTOR CORPORATION (JP) 2006-05-25 US disclosed
WO-2005072413-A2 HETEROCYCLE GRAFTED MONOMERS AND RELATED POLYMERS AND HYBRID INORGANIC-ORGANIC POLYMER MEMBRANES TOYOTA TECHNICAL CENTER, USA, INC. (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 MEN1 2008/4885KMT2A 2737/4885NPC1 200/4885
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS MGLL, LIPC, PNLIP MEN1 2569/4885KMT2A 1801/4885NPC1 258/4885
US-20060270706-A1 Cyclic amine derivative having heteroaryl ring F12, F2, H1-3 MEN1 755/4885KMT2A 2790/4885NPC1 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.